Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human Beta Defensin 2 Ameliorated Alcohol-Associated Liver Disease in Mice

ABSTRACT: Human Beta Defensin 2 in Alcohol-Associated Liver Disease

PROVIDER: PRJEB49248 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR7681520.fastq.gz	Fastqsanger.gz
	ERR7681530.fastq.gz	Fastqsanger.gz
	ERR7681540.fastq.gz	Fastqsanger.gz
	ERR7681550.fastq.gz	Fastqsanger.gz
	ERR7681560.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 118

Similar Datasets

Human Beta Defensin 2 Ameliorated Alcohol-Associated Liver Disease in Mice.

Project description:Alcohol-associated liver disease (ALD) is a prevalent liver disorder and significant global healthcare burden with limited effective therapeutic options. The gut-liver axis is a critical factor contributing to susceptibility to liver injury due to alcohol consumption. In the current study, we tested whether human beta defensin-2 (hBD-2), a small anti-microbial peptide, attenuates experimental chronic ALD. Male C57Bl/6J mice were fed an ethanol (EtOH)-containing diet for 6 weeks with daily administration of hBD-2 (1.2 mg/kg) by oral gavage during the final week. Two independent cohorts of mice with distinct baseline gut microbiota were used. Oral hBD-2 administration attenuated liver injury in both cohorts as determined by decreased plasma ALT activity. Notably, the degree of hBD-2-mediated reduction of EtOH-associated liver steatosis, hepatocellular death, and inflammation was different between cohorts, suggesting microbiota-specific mechanisms underlying the beneficial effects of hBD-2. Indeed, we observed differential mechanisms of hBD-2 between cohorts, which included an induction of hepatic and small intestinal IL-17A and IL-22, as well as an increase in T regulatory cell abundance in the gut and mesenteric lymph nodes. Lastly, hBD-2 modulated the gut microbiota composition in EtOH-fed mice in both cohorts, with significant decreases in multiple genera including Barnesiella, Parabacteroides, Akkermansia, and Alistipes, as well as altered abundance of several bacteria within the family Ruminococcaceae. Collectively, our results demonstrated a protective effect of hBD-2 in experimental ALD associated with immunomodulation and microbiota alteration. These data suggest that while the beneficial effects of hBD-2 on liver injury are uniform, the specific mechanisms of action are associated with baseline microbiota.

| S-EPMC8829467 | biostudies-literature

Effect of human beta defensin-2 (hBD-2) on T cells [mouse]

Project description:In this experiment, we studied how human beta defensin-2 (hBD-2) affects kinase activity of T cells.

2022-12-20 | GSE198404 | GEO

Effect of human beta defensin-2 (hBD-2) on T cells [human]

Project description:In this experiment, we studied how human beta defensin-2 (hBD-2) affects kinase activity of T cells.

2022-12-20 | GSE198402 | GEO

Effect of human beta defensin-2 (hBD-2) on T cells

Project description:In this experiment, we studied how human beta defensin-2 (hBD-2) affects gene expression of T cells. Murine splenic C57BL/6 CD4/CD8 T cells were stimulated with anti-CD3/anti-CD28 beads and hBD-2 or vehicle (PBS) control for 48h before RNA isolation

2022-12-23 | GSE190797 | GEO

Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease

Project description:Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1), an NAD+ synthetase in Preiss-Handler and salvage pathways, governs nuclear NAD+ homeostasis. This study investigated the role of NMNAT1 on alcohol-associated liver disease (ALD). Decreased NMNAT1 expression and activity were observed in the liver of alcohol-associated hepatitis patients and either liver or primary hepatocytes from ALD mice. F-box and WD repeat domain containing 7 (FBXW7)-regulated interferon regulatory factor 1 (IRF1) ubiquitination degradation contributed to alcohol-inhibited NMNAT1 transcriptional level. Hepatic NMNAT1 knockout aggravated alcohol-induced hepatic NAD+ decline and further hepatic steatosis and liver injury. Metabolomics and transcriptomics interaction revealed that cysteine sulfinic acid decarboxylase (CSAD)-regulated taurine pathway was involved in NMNAT1-disrupted hepatic lipid metabolism in ALD. Hepatic CSAD overexpression or taurine supply attenuated hepatic NMNAT1 knockout-aggravated ALD, respectively. Hepatic NMNAT1 loss inhibited NMN-protected ALD. Replenishing hepatic NMNAT1 reversed liver lipid accumulation in ALD mice. These findings identified NMNAT1 as a promising therapeutic target for ALD.

2025-05-25 | GSE297696 | GEO

Transcriptomics of liver and PBMCs in alcohol-associated liver disease

Project description:Transcriptomics of liver and PBMCs in alcohol-associated liver disease

| PRJNA899977 | ENA

Transcriptomics of liver and PBMCs in alcohol-associated liver disease

Project description:Transcriptomics of liver and PBMCs in alcohol-associated liver disease

| PRJNA899978 | ENA

Blockade of lL17 signaling reverses alcohol-induced liver injury, and excessive alcohol drinking in mice.

Project description:Chronic alcohol abuse has a detrimental effect on the brain and liver. There is no effective treatment for these patients and the mechanism underlying alcohol addiction and consequent alcohol-induced damage of the liver/brain axis remains unresolved. We compared experimental models of alcoholic liver disease (ALD) and alcohol dependence in mice and demonstrated that genetic ablation of IL17 Receptor A (IL17ra-/-), or pharmacological blockade of IL17 signaling effectively suppressed the increased voluntary alcohol drinking in alcohol-dependent mice, and blocked alcohol-induced hepatocellular and neurological damage. The level of circulating IL17A positively correlated with the alcohol use in excessive drinkers, and was further increased in patients with ALD as compared to healthy individuals. Our data suggest that IL17A is a common mediator of excessive alcohol consumption and alcohol-induced liver/brain injury, and targeting IL17A may provide a novel strategy for treatment of alcohol-induced pathology.

2020-04-07 | GSE137228 | GEO

Depletion of Mitochondrial Methionine Adenosyltransferase α1 Triggers Mitochondrial Dysfunction in Alcohol-Associated Liver Disease

Project description:Mitochondrial MATα1 is selectively depleted in alcohol-associated liver disease through a mechanism that involves the isomerase PIN1 and the kinase CK2. Alcohol activates CK2, which phosphorylates MATα1 at Ser114 facilitating interaction with PIN1, thereby inhibiting its mitochondrial localization. Blocking PIN1-MATα1 interaction increased mitochondrial MATα1 levels and protected against alcohol-induced mitochondrial dysfunction.

2022-02-17 | PXD030383 | Pride

Liver of alcohol-treated mouse

Project description:Liver of alcohol-treated mouse

| PRJNA782325 | ENA